

Prothena Corporation plc Investor Relations Department 331 Oyster Point Blvd South San Francisco, CA 94080 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: PRTA	
Last Trade:	11.43
Trade Time:	2:51 PM ET Apr 23, 2018
Change:	-25.41 ♣ (- 68.974%)
Day Range	11.05 - 13.70
52-Week Range	27.19 - 70.00
Volume	13,409,248

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdag: PRTA) is a global, late-stage clinical biotechnology company establishing fully integrated research, development and commercial capabilities and focused on advancing new therapies in the neuroscience and orphan categories. Fueled by a deep scientific understanding built over decades of research in protein misfolding, we seek to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Our pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson... (more)

Stock Performance



Press Releases [View all]

Apr 23, 2018

<u>Prothena Discontinues Development of</u> NEOD001 for AL Amyloidosis

Mar 20, 2018

Prothena Announces Global Neuroscience
Research & Development Collaboration with
Celgene for Novel Therapies for Patients
with Neurodegenerative Diseases

Mar 12, 2018

Prothena to Present a Broad Range of
Scientific and Health Outcomes Data at the
16th International Symposium on
Amyloidosis

Mar 7, 2018

<u>Prothena to Participate in the Barclays Global</u> <u>Healthcare Conference</u>

Feb 14, 2018

Prothena Reports Fourth Quarter and Full
Year 2017 Financial Results, and Provides
Financial Guidance and R&D Update

Financials [View all]

Fourth Quarter Financial Results

Feb 26, 2018

Annual Report (10-K)

Mar 29, 2018

Proxy Statement (DEF 14A)

Nov 7, 2017

Quarterly Report (10-Q)

Aug 9, 2017

Quarterly Report (10-Q)

May 9, 2017

Quarterly Report (10-Q)